媳妇的美好时代

China's pharmaceutical industry sees accelerated innovation breakthroughs in H1_我的网站

一 |     有投资者向欧陆通（300870.SZ）提问，请问公司在国产服务器电源领域，市占率大概多少？是否处于行业领先？是否和国内头部服务器公司比如浪潮、中科曙光（603019.SH）、新华三等有长期稳定的合作？          7月20日，公司回答表示，在数据中心电源业务国内市场方面，公司已陆续为浪潮信息（000977.SZ）、富士康、华勤、联想、中兴、新华三等国内知名服务器系统厂商出货，公司也同步与国内头部互联网企业等终端客户保持紧密合作，综合实力获得了客户的高度认可。    (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed.    China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval.    A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country.    Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category.    This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading.     At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly.    To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong.    The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions.    In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total.        (By Tang Yuxian)                    。关于具体业务及客户情况，请持续关注公司在指定信息披露平台巨潮资讯网上发布的定期报告。

Current article:http://d9617.cuntoujuefourantapai.cfd/news/20260826_55131.html

Published on:18:56:36